2. Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel).
2014;6: 1769-1792.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144: 646-674.
4. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving
paradigm. Nat Rev Cancer. 2013;13: 714-726.
5. Xie L, Bourne PE. Developing multi-target therapeutics to fine-tune the evolutionary dynamics of
the cancer ecosystem. Front Pharmacol. 2015;6: 209.
6. Abdin SM, Zaher DM, Arafa EA, Omar HA. Tackling Cancer Resistance by Immunotherapy:
Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel). 2018;10:32.
7. Zhang Z, Hou S, Chen H, et al. Targeting epigenetic reader and eraser: Rational design, synthesis
and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors. Bioorg Med
Chem Lett. 2016;26: 2931-2935.
8. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in
cancer therapy. Expert Opin Ther Targets. 2012;16: 103-119.
9. Cassinelli G, Zuco V, Gatti L, et al. Targeting the Akt kinase to modulate survival, invasiveness
and drug resistance of cancer cells. Curr Med Chem. 2013;20: 1923-1945.
10. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF
kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell.
2010;18: 683-695.
11. Regad T. Targeting RTK Signaling Pathways in Cancer. Cancers (Basel). 2015;7: 1758-1784.
12. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer.
Nat Rev Drug Discov. 2009;8: 627-644.
13. Smith A, Ni ZJ, Poon D, et al. Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF
inhibitors. Bioorg Med Chem Lett. 2017;27: 5221-5224.
14. Yang W, Chen Y, Zhou X, et al. Design, synthesis and biological evaluation of bis-aryl ureas and
amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors. Eur J Med
Chem. 2015;89: 581-596.
15. Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. The synergistic interaction of MEK
and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer. 2012;106: 1386-1394.
16. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new
frontier for drug discovery. Nat Rev Drug Discov. 2012;11: 384-400.
17. Zhang Y, Feng J, Jia Y, et al. Development of tetrahydroisoquinoline-based hydroxamic acid
derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
J Med Chem. 2011;54: 2823-2838.
18. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for
treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12: 1247-1252.
19. Ning ZQ, Li ZB, Newman MJ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase
inhibitor of the benzamide class with antitumor activity and the ability to enhance immune
cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69: 901-909.
20. Loh AHP, Stewart E, Bradley CL, et al. Combinatorial screening using orthotopic patient derived
xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
Cancer Lett. 2018;442: 262-270.
21. Kotian S, Zhang L, Boufraqech M, et al. Dual Inhibition of HDAC and Tyrosine Kinase Signaling
Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. Clin Cancer Res. 2017;23: